Logo image of SPRO

SPERO THERAPEUTICS INC (SPRO) Stock Fundamental Analysis

NASDAQ:SPRO - Nasdaq - US84833T1034 - Common Stock - Currency: USD

3.02  +0.08 (+2.72%)

After market: 2.96 -0.06 (-1.99%)

Fundamental Rating

3

SPRO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. While SPRO seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, SPRO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SPRO has reported negative net income.
In the past year SPRO has reported a negative cash flow from operations.
In the past 5 years SPRO reported 4 times negative net income.
In the past 5 years SPRO always reported negative operating cash flow.
SPRO Yearly Net Income VS EBIT VS OCF VS FCFSPRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

SPRO's Return On Assets of -89.77% is on the low side compared to the rest of the industry. SPRO is outperformed by 73.25% of its industry peers.
The Return On Equity of SPRO (-206.31%) is worse than 68.76% of its industry peers.
Industry RankSector Rank
ROA -89.77%
ROE -206.31%
ROIC N/A
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
SPRO Yearly ROA, ROE, ROICSPRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SPRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRO Yearly Profit, Operating, Gross MarginsSPRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

5

2. Health

2.1 Basic Checks

SPRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPRO has been increased compared to 1 year ago.
SPRO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SPRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SPRO Yearly Shares OutstandingSPRO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SPRO Yearly Total Debt VS Total AssetsSPRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

SPRO has an Altman-Z score of -8.05. This is a bad value and indicates that SPRO is not financially healthy and even has some risk of bankruptcy.
SPRO has a worse Altman-Z score (-8.05) than 70.74% of its industry peers.
SPRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.05
ROIC/WACCN/A
WACC9.02%
SPRO Yearly LT Debt VS Equity VS FCFSPRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

SPRO has a Current Ratio of 2.56. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
SPRO has a Current ratio of 2.56. This is in the lower half of the industry: SPRO underperforms 69.66% of its industry peers.
A Quick Ratio of 2.56 indicates that SPRO has no problem at all paying its short term obligations.
The Quick ratio of SPRO (2.56) is worse than 67.50% of its industry peers.
Industry RankSector Rank
Current Ratio 2.56
Quick Ratio 2.56
SPRO Yearly Current Assets VS Current LiabilitesSPRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

SPRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -341.51%.
SPRO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -59.83%.
SPRO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.46% yearly.
EPS 1Y (TTM)-341.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.17%
Revenue 1Y (TTM)-59.83%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-36.61%

3.2 Future

SPRO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.25% yearly.
Based on estimates for the next years, SPRO will show a quite strong growth in Revenue. The Revenue will grow by 19.51% on average per year.
EPS Next Y35.75%
EPS Next 2Y49.29%
EPS Next 3Y6.41%
EPS Next 5Y20.25%
Revenue Next Year-84.86%
Revenue Next 2Y-81.73%
Revenue Next 3Y-5.87%
Revenue Next 5Y19.51%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SPRO Yearly Revenue VS EstimatesSPRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50M 100M 150M 200M
SPRO Yearly EPS VS EstimatesSPRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

SPRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 10.39, which indicates a very decent valuation of SPRO.
Based on the Price/Forward Earnings ratio, SPRO is valued cheaply inside the industry as 95.69% of the companies are valued more expensively.
SPRO is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.03, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 10.39
SPRO Price Earnings VS Forward Price EarningsSPRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRO Per share dataSPRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.29%
EPS Next 3Y6.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SPRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPERO THERAPEUTICS INC

NASDAQ:SPRO (6/20/2025, 8:00:02 PM)

After market: 2.96 -0.06 (-1.99%)

3.02

+0.08 (+2.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners23.25%
Inst Owner Change20.62%
Ins Owners2.25%
Ins Owner Change19.11%
Market Cap168.85M
Analysts77.78
Price Target5.1 (68.87%)
Short Float %8.22%
Short Ratio0.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.63%
Min EPS beat(2)-20.18%
Max EPS beat(2)55.44%
EPS beat(4)3
Avg EPS beat(4)15.94%
Min EPS beat(4)-20.18%
Max EPS beat(4)55.44%
EPS beat(8)6
Avg EPS beat(8)115.87%
EPS beat(12)9
Avg EPS beat(12)174.93%
EPS beat(16)10
Avg EPS beat(16)130.1%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-52%
EPS NY rev (1m)35.74%
EPS NY rev (3m)-41.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-80.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.39
P/S 3.79
P/FCF N/A
P/OCF N/A
P/B 4.99
P/tB 4.99
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)0.29
Fwd EY9.63%
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.8
BVpS0.6
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -89.77%
ROE -206.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.56
Quick Ratio 2.56
Altman-Z -8.05
F-Score2
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-341.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.17%
EPS Next Y35.75%
EPS Next 2Y49.29%
EPS Next 3Y6.41%
EPS Next 5Y20.25%
Revenue 1Y (TTM)-59.83%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-36.61%
Revenue Next Year-84.86%
Revenue Next 2Y-81.73%
Revenue Next 3Y-5.87%
Revenue Next 5Y19.51%
EBIT growth 1Y-370.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-536.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-536.96%
OCF growth 3YN/A
OCF growth 5YN/A